Product Details
Alternative Name: | Core-binding factor α3 subunit, AML-2, Acute myeloid leukemia 2 protein, CBF-α3, Runt-related transcription factor 3 |
|
Clone: | R3-6E9 |
|
Host: | Mouse |
|
Isotype: | IgG1 |
|
Immunogen: | Recombinant human RUNX3 (runt-related transcription factor 3) (aa 191-300). |
|
UniProt ID: | Q13761 |
|
Species reactivity: | Human
|
|
Crossreactivity: | Weakly cross-reacts with mouse RUNX3. |
|
Applications: | IHC (PS), IP, WB
|
|
Recommended Dilutions/Conditions: | Immunohistochemistry (paraffin sections, 2µg/ml) Western Blot (0.2µg/ml) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
|
Formulation: | Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. |
|
Handling: | Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. |
|
Shipping: | Blue Ice |
|
Short Term Storage: | +4°C |
|
Long Term Storage: | -20°C |
|
Scientific Background: | RUNX (Runt-related transcription factor) family members play important roles in normal developmental processes and carcinogenesis. Of the three known RUNX family members, the ubiquitously expressed RUNX3 is involved in neurogenesis, T cell differentiation, tumorigenesis and is a component of the TGF-β induced tumor suppressor pathway. In gastric cancer cells, RUNX3 induces cell cycle arrest and apoptosis through upregulation of Bim, a proapoptotic BH3-only protein. In addition, RUNX3 is frequently inactivated in gastric cancer cells. |
|
Regulatory Status: | RUO - Research Use Only |
|
Figure 1: Western blot analysis using MAb to RUNX3 (human) (R3-6E9) (Prod. No.
ALX-803-318).
Method: 0.2µg/ml of MAb to RUNX3 (human) (R3-6E9) were applied to the membrane on which recombinant human (lanes 1-3) or mouse (lanes 4-6) RUNX1, RUNX2 or RUNX3 expressed in COS7 cells were loaded (see [1])."
Figure 2: Immunohistochemistry using MAb to RUNX3 (human) (R3-6E9) (Prod. No.
ALX-803-318).
Method: 2µg/ml of MAb to RUNX3 (human) (R3-6E9) were applied to normal human gastic samples (paraffin sections) which were retrieved by autoclave at 105°C for 15 min. in Dako solution (see [1])."
Please mouse over
Product Literature References
Targets of genome copy number reduction in primary breast cancers identified by integrative genomics: W. Chen, et al.; Genes Chromosomes Cancer
46, 288 (2007),
Abstract;
RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer: Q.C. Lau, et al.; Cancer Res.
66, 6512 (2006),
Abstract;
Full Text
RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization: K. Ito, et al.; Cancer Res.
65, 7743 (2005),
Abstract;
Full Text
General Literature References
The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis: T. Yano, et al.; Mol. Cell. Biol.
26, 4474 (2006),
Abstract;
Full Text
Tumor suppressor activity of RUNX3: S.C. Bae & J.K. Choi; Oncogene
23, 4336 (2004),
Abstract;